Paclitaxel and Carboplatin Combination Chemotherapy in a Hemodialysis Patient with Advanced Ovarian Cancer

By Watanabe M.   Aoki Y.   Tomita M.   Sato T.   Takaki Y.   Kato N.   Kikuchi M.   Kase H.   Tanaka K.  

Gynecologic Oncology, Vol. 84, Iss. 2, 2002-02 ,pp. : 335-338

Elsevier

Access to resources Recommend Favorite

Cost-Utility Analysis of Paclitaxel in Combination with Cisplatin for Patients with Advanced Ovarian Cancer

By Ortega A.   Dranitsaris G.   Sturgeon J.   Sutherland H.   Oza A.  

Gynecologic Oncology, Vol. 66, Iss. 3, 1997-09 ,pp. : 454-463

Elsevier

Access to resources Recommend Favorite

Cisplatin-Paclitaxel-Cyclophosphamide with G-CSF in Primary Advanced Epithelial Ovarian Cancer

By Fanning J.   Colgrove M.   Phibbs G.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 97-100

Elsevier

Access to resources Recommend Favorite

Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study

By De Lena M.   Lorusso V.   Latorre A.   Fanizza G.   Gargano G.   Caporusso L.   Guida M.   Catino A.   Crucitta E.   Sambiasi D.   Mazzei A.  

European Journal of Cancer, Vol. 37, Iss. 3, 2001-02 ,pp. : 364-368

Elsevier

Access to resources Recommend Favorite

A Phase II Study of the MDR Inhibitor Biricodar (INCEL, VX-710) and Paclitaxel in Women with Advanced Ovarian Cancer Refractory to Paclitaxel Therapy

By Seiden M.V.   Swenerton K.D.   Matulonis U.   Campos S.   Rose P.   Batist G.   Ette E.   Garg V.   Fuller A.   Harding M.W.   Charpentier D.  

Gynecologic Oncology, Vol. 86, Iss. 3, 2002-09 ,pp. : 302-310

Academic Press

Access to resources Recommend Favorite